Inovio announces new data at scientific conferences for lead candidate, ino-3107, as a potential treatment for rrp

American association for cancer research (aacr) special conference: tumor immunology and immunotherapy : new immunology data showed ability of ino-3107 to induce an antigen-specific t cell response against hpv-6 and hpv-11 and drive recruitment of t cells into airway tissues and papilloma international society of vaccines conference : full safety and efficacy data from phase 1/2 clinical study in patients with recurrent respiratory papillomatosis (rrp) indicated that ino-3107 was well tolerated and immunogenic; 81% of patients in the trial required fewer surgeries post-treatment when compared to baseline plymouth meeting, pa. , oct. 21, 2024 /prnewswire/ -- inovio (nasdaq:ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv-related diseases, cancer, and infectious diseases, today announced the presentation of new data at scientific conferences for its lead candidate, ino-3107, for which the company is preparing a biologics license application for targeted submission in mid-2025 under the u.s. food and drug administration's accelerated approval pathway program.
INO Ratings Summary
INO Quant Ranking